Australia's CSL surges 18% on earnings beat, upbeat plasma business forecast

Australian biotechnology giant CSL saw its shares surge 18%, marking its best intraday session since 2001, after reporting better-than-expected annual underlying earnings. The company forecast growth for 2027 driven by its core plasma division, boosting investor confidence in the world's top flu vaccine maker.

By Sherin Sunny and Nikita Maria Jino Aug 18 (Reuters) - CSL reported better-than-expected annual underlying earnings on Tuesday and forecast growth in 2027 on the back of its core plasma division, sending the Australian biotechnology giant's shares up 18% in their best intraday session since 2001. CSL, among the world's top flu vaccine makers, posted underlying net profit after tax attributable